[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 711, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 56, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 47, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 71, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 71, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy  Davis M.B.A.", "title": "SVP of Cardiovascular & Head of Metabolic Franchise", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 66.25, "open": 66.45, "dayLow": 63.69, "dayHigh": 66.7315, "regularMarketPreviousClose": 66.25, "regularMarketOpen": 66.45, "regularMarketDayLow": 63.69, "regularMarketDayHigh": 66.7315, "payoutRatio": 0.0, "beta": 1.218, "forwardPE": -14.151288, "volume": 1543407, "regularMarketVolume": 1543407, "averageVolume": 2623722, "averageVolume10days": 3699410, "averageDailyVolume10Day": 3699410, "bid": 63.46, "ask": 64.07, "bidSize": 13, "askSize": 13, "marketCap": 8899847168, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 76.76, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 10.729843, "fiftyDayAverage": 57.812, "twoHundredDayAverage": 30.47265, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8533961216, "profitMargins": -0.0019699999, "floatShares": 117185993, "sharesOutstanding": 139408632, "sharesShort": 9626302, "sharesShortPriorMonth": 11836793, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0708, "heldPercentInsiders": 0.043390002, "heldPercentInstitutions": 0.84133005, "shortRatio": 3.6, "shortPercentOfFloat": 0.0919, "impliedSharesOutstanding": 139408633, "bookValue": 3.434, "priceToBook": 18.590565, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -1631000, "trailingEps": -0.01, "forwardEps": -4.51125, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 10.289, "enterpriseToEbitda": 69.794, "52WeekChange": 2.352733, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 63.84, "targetHighPrice": 110.0, "targetLowPrice": 35.0, "targetMeanPrice": 78.2, "targetMedianPrice": 80.5, "recommendationMean": 1.76923, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 917465984, "totalCashPerShare": 6.756, "ebitda": 122274000, "totalDebt": 743980992, "quickRatio": 4.728, "currentRatio": 4.863, "totalRevenue": 829448000, "debtToEquity": 147.787, "revenuePerShare": 6.201, "returnOnAssets": 0.04868, "returnOnEquity": 0.08672, "grossProfits": 829448000, "freeCashflow": 96153624, "operatingCashflow": 179552000, "grossMargins": 1.0, "ebitdaMargins": 0.14741999, "operatingMargins": 0.17197001, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768610893, "regularMarketTime": 1768597201, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.63774, "regularMarketPrice": 63.84, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": 0.3289519, "postMarketPrice": 64.05, "postMarketChange": 0.2100029, "regularMarketChange": -2.41, "regularMarketDayRange": "63.69 - 66.7315", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2623722, "fiftyTwoWeekLowChange": 54.27, "fiftyTwoWeekLowChangePercent": 5.6708465, "fiftyTwoWeekRange": "9.57 - 76.76", "fiftyTwoWeekHighChange": -12.920002, "fiftyTwoWeekHighChangePercent": -0.16831686, "fiftyTwoWeekChangePercent": 235.27328, "earningsTimestampStart": 1770670800, "earningsTimestampEnd": 1770670800, "earningsCallTimestampStart": 1754598600, "earningsCallTimestampEnd": 1754598600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.01, "epsForward": -4.51125, "epsCurrentYear": -3.437, "priceEpsCurrentYear": -18.574337, "fiftyDayAverageChange": 6.028, "fiftyDayAverageChangePercent": 0.104269005, "twoHundredDayAverageChange": 33.367348, "twoHundredDayAverageChangePercent": 1.0949932, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "marketState": "CLOSED", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]